Tested Applications
| Positive IHC detected in | human lung tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | Hela cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
20039-1-AP targets PDZD2 in WB, IHC, IF/ICC, IP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | PDZ domain containing 2 |
| Calculated Molecular Weight | 302 kDa |
| GenBank Accession Number | NM_178140 |
| Gene Symbol | PDZD2 |
| Gene ID (NCBI) | 23037 |
| RRID | AB_10697686 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O15018 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
PDZD2, also named as AIPC, KIAA0300 and PDZK3, may be associated with the early promotion of prostate tumoregenesis. The antibody recognizes near the N-term of PDZD2.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for PDZD2 antibody 20039-1-AP | Download protocol |
| IHC protocol for PDZD2 antibody 20039-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The PDZD2 Polyclonal antibody (Cat# 20039-1-AP) has a total of 1 citation. It was published in Cancer Biology & Medicine (IF: 12.4) in 2025, in a study investigating how MDM1 overexpression promotes p53 expression and cell apoptosis to enhance therapeutic sensitivity to chemoradiotherapy in patients with colorectal cancer. The antibody was used for Western blot and immunoprecipitation in human samples. The associated research field is oncology, specifically colorectal cancer and chemoradiotherapy response.
| Species | Application | Title |
|---|---|---|
Cancer Biol Med MDM1 overexpression promotes p53 expression and cell apoptosis to enhance therapeutic sensitivity to chemoradiotherapy in patients with colorectal cancer |





